{
  "id": "5891b125621ea6ff7e00000e",
  "type": "factoid",
  "question": "Which disease is treated with taliglucerase alfa?",
  "ideal_answer": "Taliglucerase alfa, the first available plant cell-expressed recombinant therapeutic protein, is an enzyme replacement therapy approved for Gaucher disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27102949",
    "http://www.ncbi.nlm.nih.gov/pubmed/23980545",
    "http://www.ncbi.nlm.nih.gov/pubmed/27174694",
    "http://www.ncbi.nlm.nih.gov/pubmed/21235447",
    "http://www.ncbi.nlm.nih.gov/pubmed/24630271",
    "http://www.ncbi.nlm.nih.gov/pubmed/21900191",
    "http://www.ncbi.nlm.nih.gov/pubmed/27499018",
    "http://www.ncbi.nlm.nih.gov/pubmed/26053270",
    "http://www.ncbi.nlm.nih.gov/pubmed/22654679",
    "http://www.ncbi.nlm.nih.gov/pubmed/23199589",
    "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
    "http://www.ncbi.nlm.nih.gov/pubmed/27839981",
    "http://www.ncbi.nlm.nih.gov/pubmed/25453586",
    "http://www.ncbi.nlm.nih.gov/pubmed/23046562",
    "http://www.ncbi.nlm.nih.gov/pubmed/27559188",
    "http://www.ncbi.nlm.nih.gov/pubmed/25812601",
    "http://www.ncbi.nlm.nih.gov/pubmed/22916340"
  ],
  "snippets": [
    {
      "text": "Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Taliglucerase alfa is the first available plant cell-expressed human recombinant therapeutic protein. It is indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several countries. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 36-month results of switching from imiglucerase to taliglucerase alfa treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond the initial 9 months of the original study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-na\u00efve patients with Gaucher disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher disease (GD), and is the first available plant cell-expressed recombinant therapeutic protein. Herein, we report long-term safety and efficacy results of taliglucerase alfa in treatment-na\u00efve adult patients with GD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " These 36-month results of taliglucerase alfa in treatment-na\u00efve adult patients with GD demonstrate continued improvement in disease parameters with no new safety concerns.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-na\u00efve patients with Gaucher disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27499018",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Taliglucerase alfa, the first available plant cell-expressed recombinant therapeutic protein, is an enzyme replacement therapy approved for Gaucher disease (GD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27499018",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na\u00efve or previously treated with imiglucerase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27839981",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These results support safety and efficacy of taliglucerase alfa for Gaucher disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21900191",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199589",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Taliglucerase alfa for the treatment of Gaucher's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22916340",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These results support safety and efficacy of taliglucerase alfa for Gaucher disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21900191",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This multicenter, randomized, double-blind, parallel-dose, 12-month study assessed efficacy and safety of taliglucerase alfa in pediatric patients with GD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A Phase 3, multicenter, open-label, 9-month study assessed safety and efficacy of switching to taliglucerase alfa in adult and pediatric patients with GD treated with imiglucerase for at least the previous 2years",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical trials have demonstrated that taliglucerase alfa is efficacious, with a well-established safety profile in adult, ERT-na\u00efve patients with symptomatic GD1, and for such patients previously treated with imiglucerase",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630271",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "One study examined substrate reduction therapy in people with chronic neuronopathic (type 3) Gaucher disease who continued to receive enzyme replacement therapy.Treatment-na\u00efve participants had similar increases in haemoglobin when comparing those receiving imiglucerase or alglucerase at 60 units/kg, imiglucerase or velaglucerase alfa at 60 U/kg, taliglucerase alfa at 30 units/kg or 60 units/kg, and velaglucerase alfa at 45 units/g or 60 units/kg. For platelet count response in participants with intact spleens, a benefit for imiglucerase over velaglucerase alfa at 60 units/kg was observed, mean difference -79.87 (95% confidence interval -137.57 to -22.17)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25812601",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Taliglucerase alfa (Protalix Biotherapeutics, Israel) is a carrot-cell-expressed recombinant human beta-glucocerebrosidase recently approved in the United States for the treatment of type 1 Gaucher disease (GD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199589",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These 36-month results of taliglucerase alfa in treatment-na\u00efve adult patients with GD demonstrate continued improvement in disease parameters with no new safety concerns.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Phase 3, multicenter, open-label, 9-month study assessed safety and efficacy of switching to taliglucerase alfa in adult and pediatric patients with GD treated with imiglucerase for at least the previous 2years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical trials have demonstrated that taliglucerase alfa is efficacious, with a well-established safety profile in adult, ERT-na\u00efve patients with symptomatic GD1, and for such patients previously treated with imiglucerase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630271",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These data suggest that taliglucerase alfa has the potential to be a therapeutic treatment option for children with GD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na\u00efve or previously treated with imiglucerase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27839981",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:4",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"
  ],
  "exact_answer": "Gaucher disease"
}